Cilengitide inhibits attachment and invasion of malignant pleural mesothelioma cells through antagonism of integrins αvβ3 and αvβ5

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Cheng, Ngan Ching ^a   Van Zandwijk, Nico ^a   Reid, Glen ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHAVBETA5 INTEGRIN; CILENGITIDE; VITRONECTIN RECEPTOR; SNAKE VENOM;

ANOIKIS; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL DESTRUCTION; CANCER INHIBITION; CELL ADHESION; CELL DETACHMENT; CELL VIABILITY; CELLULAR PARAMETERS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG CYTOTOXICITY; DRUG MECHANISM; GENE SILENCING; IN VITRO STUDY; MESOTHELIUM CELL; PLEURA MESOTHELIOMA; PROTEIN EXPRESSION; RECEPTOR BLOCKING; RECEPTOR DOWN REGULATION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; HUMAN; MESOTHELIOMA; NEOPLASM INVASIVENESS; PATHOLOGY; PLEURA TUMOR; TUMOR CELL LINE;

CELL ADHESION; CELL LINE, TUMOR; HUMANS; INTEGRIN ALPHAVBETA3; MESOTHELIOMA; NEOPLASM INVASIVENESS; PLEURAL NEOPLASMS; RECEPTORS, VITRONECTIN; SNAKE VENOMS;

EID: 84896978053     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090374     Document Type: Article

References (41)

1. Robinson BW, Lake RA (2005) Advances in malignant mesothelioma. N Engl J Med 353: 1591-1603. (Pubitemid 41434638)
2. Zervos MD, Bizekis C, Pass HI (2008) Malignant mesothelioma 2008. Curr Opin Pulm Med 14: 303-309. (Pubitemid 351786540)
3. Tsao AS, Wistuba I, Roth JA, Kindler HL (2009) Malignant pleural mesothelioma. J Clin Oncol 27: 2081-2090.
4. Lechner JF, Tokiwa T, LaVeck M, Benedict WF, Banks-Schlegel S, et al. (1985) Asbestos-associated chromosomal changes in human mesothelial cells. Proc Natl Acad Sci U S A 82: 3884-3888. (Pubitemid 15246457)
5. Hynes RO (2002) Integrins: bidirectional, allosteric signaling machines. Cell 110: 673-687.
6. Marshall JF, Hart IR (1996) The role of alpha v-integrins in tumour progression and metastasis. Semin Cancer Biol 7: 129-138. (Pubitemid 26179260)
7. Folkman J, Watson K, Ingber D, Hanahan D (1989) Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339: 58-61. (Pubitemid 19115892)
8. Byzova TV, Rabbani R, D'Souza SE, Plow EF (1998) Role of integrin alpha(v)beta3 in vascular biology. Thromb Haemost 80: 726-734. (Pubitemid 28521714)
9. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, et al. (1994) Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79: 1157-1164.
10. Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, et al. (1995) Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 96: 1815-1822.
11. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, et al. (1995) Definition of two angiogenic pathways by distinct alpha v integrins. Science 270: 1500-1502. (Pubitemid 3005294)
12. Hammes HP, Brownlee M, Jonczyk A, Sutter A, Preissner KT (1996) Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nat Med 2: 529-533. (Pubitemid 26151516)
13. Nisato RE, Tille JC, Jonczyk A, Goodman SL, Pepper MS (2003) alphav beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro. Angiogenesis 6: 105-119. (Pubitemid 38173862)
14. Oliveira-Ferrer L, Hauschild J, Fiedler W, Bokemeyer C, Nippgen J, et al. (2008) Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway. J Exp Clin Cancer Res 27: 86.
15. Mikkelsen T, Brodie C, Finniss S, Berens ME, Rennert JL, et al. (2009) Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency. Int J Cancer 124: 2719-2727.
16. MacDonald TJ, Taga T, Shimada H, Tabrizi P, Zlokovic BV, et al. (2001) Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist. Neurosurgery 48: 151-157. (Pubitemid 32039837)
17. Nabors LB, Mikkelsen T, Rosenfeld SS, Hochberg F, Akella NS, et al. (2007) Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol 25: 1651-1657. (Pubitemid 46797943)
18. Reardon DA, Cheresh D (2011) Cilengitide: a prototypic integrin inhibitor for the treatment of glioblastoma and other malignancies. Genes Cancer 2: 1159-1165.
19. Desgrosellier JS, Cheresh DA (2010) Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10: 9-22.
20. Flores RM, Zakowski M, Venkatraman E, Krug L, Rosenzweig K, et al. (2007) Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. J Thorac Oncol 2: 957-965. (Pubitemid 47511601)
21. Koukoulis GK, Shen J, Monson R, Warren WH, Virtanen I, et al. (1997) Pleural mesotheliomas have an integrin profile distinct from visceral carcinomas. Hum Pathol 28: 84-90. (Pubitemid 27044487)
22. Klominek J, Sumitran Karuppan S, Hauzenberger D (1997) Differential motile response of human malignant mesothelioma cells to fibronectin, laminin and collagen type IV: the role of beta1 integrins. Int J Cancer 72: 1034-1044. (Pubitemid 27433570)
23. Sigstad E, Dong HP, Nielsen S, Berner A, Davidson B, et al. (2005) Quantitative analysis of integrin expression in effusions using flow cytometric immunophenotyping. Diagn Cytopathol 33: 325-331. (Pubitemid 41598053)
24. Pass HI, Lott D, Lonardo F, Harbut M, Liu Z, et al. (2005) Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 353: 1564-1573. (Pubitemid 41434635)
25. Cristaudo A, Bonotti A, Simonini S, Vivaldi A, Guglielmi G, et al. (2011) Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma. J Thorac Oncol 6: 1587-1593.
26. Boylan AM, Sanan DA, Sheppard D, Broaddus VC (1995) Vitronectin enhances internalization of crocidolite asbestos by rabbit pleural mesothelial cells via the integrin alpha v beta 5. J Clin Invest 96: 1987-2001.
27. Goodman SL, Grote HJ, Wilm C (2012) Matched rabbit monoclonal antibodies against alphav-series integrins reveal a novel alphavbeta3-LIBS epitope, and permit routine staining of archival paraffin samples of human tumors. Biol Open 1: 329-340.
28. Maurer GD, Tritschler I, Adams B, Tabatabai G, Wick W, et al. (2009) Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro. Neuro Oncol 11: 747-756.
29. Frisch SM, Francis H (1994) Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 124: 619-626. (Pubitemid 24064472)
30. Simpson CD, Anyiwe K, Schimmer AD (2008) Anoikis resistance and tumor metastasis. Cancer Lett 272: 177-185.
31. Taddei ML, Giannoni E, Fiaschi T, Chiarugi P (2012) Anoikis: an emerging hallmark in health and diseases. J Pathol 226: 380-393.
32. Alghisi GC, Ponsonnet L, Ruegg C (2009) The integrin antagonist cilengitide activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells. PLoS One 4: e4449.
33. Tentori L, Dorio AS, Muzi A, Lacal PM, Ruffini F, et al. (2008) The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma. Oncol Rep 19: 1039-1043. (Pubitemid 351802678)
34. Kim YH, Lee JK, Kim B, Dewitt JP, Lee JE, et al. (2013) Combination therapy of cilengitide with belotecan against experimental glioblastoma. Int J Cancer.
35. Wiggins H, Rappoport J (2010) An agarose spot assay for chemotactic invasion. Biotechniques 48: 121-124.
36. Vermorken JB, Guigay J, Mesia R, Trigo JM, Keilholz U, et al. (2011) Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part. Br J Cancer 104: 1691-1696.
37. O'Donnell PH, Undevia SD, Stadler WM, Karrison TM, Nicholas MK, et al. (2012) A phase I study of continuous infusion cilengitide in patients with solid tumors. Invest New Drugs 30: 604-610.
38. Leblond P, Dewitte A, Le Tinier F, Bal-Mahieu C, Baroncini M, et al. (2013) Cilengitide targets pediatric glioma and neuroblastoma cells through cell detachment and anoikis induction. Anticancer Drugs.
39. Barth TF, Bruderlein S, Rinaldi N, Mechtersheimer G, Moller P (1997) Pleural mesothelioma mimics the integrin profile of activated, sessile rather than detached mesothelial cells. Int J Cancer 72: 77-86. (Pubitemid 27314643)
40. Relan V, Morrison L, Parsonson K, Clarke BE, Duhig EE, et al. (2013) Phenotypes and karyotypes of human malignant mesothelioma cell lines. PLoS One 8: e58132.
41. Smythe WR, Kaiser LR, Hwang HC, Amin KM, Pilewski JM, et al. (1994) Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma. The Annals of thoracic surgery 57: 1395-1401. (Pubitemid 24216301)